Merck & Co., Inc. (MRK)
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma. A decision is due on May 26, 2025.
Merck (MRK) Earnings Expected to Grow: Should You Buy?
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?
When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer
The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
Last year wasn't a good one for Merck (MRK -1.12%), one of the largest pharmaceutical companies in the world. The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine Keytruda.
Kennedy would keep legal fees from Merck cases if confirmed
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President Donald Trump's secretary of the U.S. Department of Health and Human Services, according to a federal ethics disclosure made public on Wednesday.
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Merck (MRK) closed at $96.24, marking a -1.72% move from the previous day.
Merck: 3x Pipeline And Undervaluation Make It A Buy
Merck's current discounted valuation, and robust pipeline advancements, which tripled over the past 3+ years, present a compelling long-term investment opportunity. Its strong business performance with 7% YoY revenue growth, driven by Keytruda and GARDASIL expansions, supports Merck's solid financial health. Merck's 3.3% dividend yield, low net debt-to-EBITDA ratio, and promising late-stage assets enhance its appeal for value and income-oriented investors.
High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent
A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Merck's robust Phase 3 pipeline, strong financials, and sustainable dividend make it a compelling investment despite risks like Medicare negotiations and patent expirations. Merck also appears to have good potential for future growth.
Exclusive: Kennedy played key role in vaccine case against Merck
Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los Angeles court next week, according to two attorneys close to the case and court filings.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
What's In Store For Merck Stock In 2025?
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly stock (up 31%) and AbbVie stock(up 15%), Merck's stock performance has been muted.
